Clinical cases of treatment of patient with primary biliary cirrhosis by аutologous bone marrow cell transplantation

Клинический случай лечения первичного билиарного цирроза печени мононуклеарными клетками аутологичного костного мозга
Venera Rakhmetova 1, Saltanat Tuganbekova 1, Galiya Shaimardanova 1, Manarbek Askarov 1, Karlygash Kuzembayeva 1, Yelena Svetlichnaya 1
More Detail
1 National Scientific Medical Research Center, Astana, Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 35, pp. 62-65.
OPEN ACCESS 2897 Views 2069 Downloads
Download Full Text (PDF)

ABSTRACT

This article reviews a clinical study of autologous bone marrow cell infusion (ABMI) therapy for treatment of primary biliary cirrhosis, II stage. After the second and third transplantation of barrel cages a patient marked regress of skin itch, decreased hyperpigmentation, expressed of asthenic syndrome, decline of level of markers of cytolysis and cholestasia. A control liver-biopsy educed reduction of dystrophic changes in hepatocytes, decline of inflammatory infiltration.
Keywords: primary biliary cirrhosis, mononuclear cells, bone marrow

CITATION

Rakhmetova V, Tuganbekova S, Shaimardanova G, Askarov M, Kuzembayeva K, Svetlichnaya Y. Clinical cases of treatment of patient with primary biliary cirrhosis by аutologous bone marrow cell transplantation. Journal of Clinical Medicine of Kazakhstan. 2015;1(35):62-5.

REFERENCES

  • Autoimmunnye zabolevanija pecheni v praktike klinicista (Autoimmune diseases of the liver in the practice of clinicians), V.T.Ivashkin, A. O.Bueverov, M., M-Vesti, 2001, 102 p.
  • Sheptulina A.F., Maevskaja M.V., Ivashkin V.T. Kriticheskaja ocenka patogeneticheskih faktorov pervichnogo biliarnogo cirroza (A critical evaluation of the pathogenic factors of primary biliary cirrhosis), Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii, 2013, No.3, pp.39-48.
  • Cimmerman Ja. S., Lejshner U. Autoimmunnye zabolevanija pecheni i perekrestnyj sindrom (Autoimmune diseases of the liver and the cross syndrome), Klinicheskaja medicina, 2006, T. 84, No. 2, pp. 75-74.
  • James OFD. Definition and epidemiology of primary biliary cirrhosis. In: Nueberger J (Hrsg), Primary biliary cirrhosis, West End Studios Ltd, Eastbourne, UK, 1999, pp.53-59.
  • Shi J., Wu C., Lin Y. – X.et al. Long –term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a metaanalysis of randomized controlled trials, Am. J. Gastroenterol, 2006, No.101, pp.1529-1538.
  • Takeuchi Y., Ikeda F., Fujioka S.I. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid, J. Gastroenterol. Hepatol, 2011, No.10, pp.1440-1746.
  • Shumakov V.I., Onishhenko N.A. Biologicheskie rezervy kletok kostnogo mozga i korrekcija organnyh disfunkcij (Biological reserves of bone marrow cells and correction of organ dysfunction), M. «Lavr», 2009, 286 p.
  • Shevchenko Ju.L.. Kletochnaja terapija autoimmunnyh zabolevanij (Cell therapy of autoimmune diseases), SPb, 2009, 120 p.